ANPA 0073
Alternative Names: ANPA-0073Latest Information Update: 13 Mar 2025
At a glance
- Originator Annapurna Bio
- Class Antifibrotics; Small molecules
- Mechanism of Action Apelin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Pulmonary arterial hypertension
- Preclinical Idiopathic pulmonary fibrosis
Most Recent Events
- 13 Mar 2025 Phase-I development ongoing in Pulmonary-arterial-hypertension(In volunteers) in Australia (PO, Capsule) (Structure Therapeutics pipeline, March 2025)
- 19 May 2023 Safety and Pharmacokinetics data from a phase I trial in Pulmonary arterial hypertension (In Volunteers) presented at 119th International Conference of the American Thoracic Society (ATS-2023)
- 08 May 2023 Annapurna Bio plans to initiate a phase II study in the US in 2024